BioAtla Inc. (NASDAQ: BCAB)
$1.75
-0.0500 ( -2.78% ) 938.9K
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Market Data
Open
$1.75
Previous close
$1.80
Volume
938.9K
Market cap
$84.20M
Day range
$1.66 - $1.89
52 week range
$1.14 - $4.02
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jul 01, 2024 |
4 | Insider transactions | 1 | Jul 01, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
8-k | 8K-related | 11 | Jun 13, 2024 |
4 | Insider transactions | 1 | May 31, 2024 |